1 Table of Contents 2
1.1 LIST OF FIGURES 4
1.2 LIST OF TABLES 5

2 Executive Summary 6
2.1 DISEASE OVERVIEW 6
2.2 PIPELINE SNAPSHOT 7
2.3 PIPELINE DRUGS BY PHASE 7
2.4 PIPELINE DRUGS BY COMPANY 9
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION 12

3 Portal Hypertension- Company wise Pipeline Analysis 15
3.1 Conatus Pharmaceuticals PIPELINE, H1 2018 15
3.2 Cumberland Pharmaceuticals PIPELINE, H1 2018 15
3.3 Galectin Therapeutics PIPELINE, H1 2018 16
3.4 Mezzion Pharma Co. Ltd. PIPELINE, H1 2018 16
3.5 LinXis B.V. PIPELINE, H1 2018 17
3.6 Novartis Pharmaceuticals PIPELINE, H1 2018 17
3.7 Ono Pharmaceuticals PIPELINE, H1 2018 18
3.8 Ferring Pharmaceuticals PIPELINE, H1 2018 18

4 Portal Hypertension Drug Snapshots 19
4.1 Emricasan Drug Details 19
4.1.1 Snapshot 19
4.1.2 Drug Overview 19
4.1.3 Mechanism of Action 19
4.1.4 Current Status 19
4.1.5 Trial Details 19
4.2 Portaban Drug Details 21
4.2.1 Snapshot 21
4.2.2 Drug Overview 21
4.2.3 Mechanism of Action 21
4.2.4 Current Status 21
4.2.5 Trial Details 21
4.3 GR-MD-02 Drug Details 22
4.3.1 Snapshot 22
4.3.2 Drug Overview 22
4.3.3 Mechanism of Action 22
4.3.4 Current Status 22
4.3.5 Trial Details 22
4.4 Udenafil Drug Details 24
4.4.1 Snapshot 24
4.4.2 Drug Overview 24
4.4.3 Mechanism of Action 24
4.4.4 Current Status 24
4.4.5 Trial Details 24
4.5 LxL-001 Drug Details 26
4.5.1 Snapshot 26
4.5.2 Drug Overview 26
4.5.3 Mechanism of Action 26
4.5.4 Current Status 26
4.6 Serelaxin Drug Details 27
4.6.1 Snapshot 27
4.6.2 Drug Overview 27
4.6.3 Mechanism of Action 27
4.6.4 Current Status 27
4.6.5 Trial Details 27
4.7 ONO 1266 Drug Details 28
4.7.1 Snapshot 28
4.7.2 Drug Overview 28
4.7.3 Mechanism of Action 28
4.7.4 Current Status 28
4.7.5 Trial Details 28
4.8 FE 204205 Drug Details 29
4.8.1 Snapshot 29
4.8.2 Drug Overview 29
4.8.3 Mechanism of Action 29
4.8.4 Current Status 29
4.8.5 Trial Details 29

5 Appendix 30
5.1 ABOUT VPA RESEARCH 30
5.2 SOURCES AND RESEARCH METHODOLOGY 30

1.1 LIST OF FIGURES
Figure 1: Portal Hypertension Pipeline by Phase, H1- 2018 8
Figure 2: Portal Hypertension Pipeline by Companies, H1- 2018 10
Figure 3: Company wise Pipeline Drug Phases, H1- 2018 11
Figure 4: Portal Hypertension Pipeline by Mechanism of Action, H1- 2018 13
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018 14

1.2 LIST OF TABLES
Table 1: Portal Hypertension Pipeline by Phase, H1- 2018 7
Table 2: Portal Hypertension Pipeline by Companies, H1- 2018 (1) 9
Table 3: Portal Hypertension Pipeline by Mechanism of Action, H1- 2018 12
Table 4: Conatus Pharmaceuticals - Portal Hypertension Pipeline, H1- 2018 15
Table 5: Cumberland Pharmaceuticals Portal Hypertension Pipeline, H1- 2018 15
Table 6: Galectin Therapeutics Portal Hypertension Pipeline, H1- 2018 16
Table 7: Mezzion Pharma Co. Ltd. - Portal Hypertension Pipeline, H1- 2018 16
Table 8: LinXis B.V. - Portal Hypertension Pipeline, H1- 2018 17
Table 9: Novartis Pharmaceuticals - Portal Hypertension Pipeline, H1- 2018 17
Table 10: Ono Pharmaceuticals - Portal Hypertension Pipeline, H1- 2018 18
Table 11: Ferring Pharmaceuticals - Portal Hypertension Pipeline, H1- 2018 18

Companies Mentioned
• Conatus Pharmaceuticals
• Cumberland Pharmaceuticals
• Galectin Therapeutics
• Mezzion Pharma Co. Ltd.
• LinXis B.V.
• Novartis Pharmaceuticals
• Ono Pharmaceutical
• Ferring Pharmaceuticals
• Conatus Pharmaceuticals
• Bristol-Myers Squibb
• Providence Cancer Center
• Dr. Falk Pharma GmbH
• LinXis B.V.
• University of Edinburgh
• Providence Health & Services
• University of Bonn
• Groningen Research Institute of Pharmacy
• NHS Lothian